Royce & Associates LP increased its position in MeiraGTx Holdings plc (NASDAQ:MGTX – Free Report) by 5.3% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 795,392 shares of the company’s stock after purchasing an additional 40,000 shares during the period. Royce & Associates LP owned 1.23% of MeiraGTx worth $3,317,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. grew its position in shares of MeiraGTx by 1.9% in the 1st quarter. Russell Investments Group Ltd. now owns 157,999 shares of the company’s stock worth $959,000 after acquiring an additional 2,994 shares in the last quarter. Letko Brosseau & Associates Inc. boosted its holdings in MeiraGTx by 38.5% in the second quarter. Letko Brosseau & Associates Inc. now owns 45,300 shares of the company’s stock worth $191,000 after purchasing an additional 12,600 shares during the period. Squarepoint Ops LLC acquired a new position in MeiraGTx in the second quarter worth $123,000. American Century Companies Inc. increased its stake in MeiraGTx by 42.4% during the second quarter. American Century Companies Inc. now owns 40,008 shares of the company’s stock valued at $168,000 after purchasing an additional 11,907 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of MeiraGTx by 14.6% during the second quarter. Dimensional Fund Advisors LP now owns 462,950 shares of the company’s stock worth $1,949,000 after purchasing an additional 58,854 shares during the period. 67.48% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Several research firms have recently commented on MGTX. Royal Bank of Canada lifted their price target on shares of MeiraGTx from $9.00 to $11.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. Chardan Capital restated a “buy” rating and issued a $36.00 target price on shares of MeiraGTx in a research note on Monday.
MeiraGTx Price Performance
Shares of NASDAQ MGTX opened at $6.09 on Tuesday. MeiraGTx Holdings plc has a 1-year low of $3.85 and a 1-year high of $7.60. The firm has a market capitalization of $475.95 million, a PE ratio of -5.03 and a beta of 1.24. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.34 and a quick ratio of 2.36. The business’s fifty day moving average price is $5.17 and its two-hundred day moving average price is $4.80.
About MeiraGTx
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.
Read More
- Five stocks we like better than MeiraGTx
- Basic Materials Stocks Investing
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Applied Materials Market Capitulates: Now is the Time to Buy
- How to Most Effectively Use the MarketBeat Earnings Screener
- 3 Ultra-High Dividend Yield Stocks for the New Year
Want to see what other hedge funds are holding MGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MeiraGTx Holdings plc (NASDAQ:MGTX – Free Report).
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.